Clinical studies under development

NeuroVia’s lead drug candidate, NV1205, is being developed for the treatment of X-linked Adrenoleukodystrophy (X-ALD).

Learn More

Working with patients and doctors to control this disease.

NV1205 is an orally administered clinical-stage drug candidate that was shown to be safe and well-tolerated in Phase 1 clinical studies.

Learn More